Roche Announces Changes to Board of Directors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Roche Announces Changes to Board of Directors



Roche has proposed that the following members of its board of directors be re-elected at the company’s annual general meeting, scheduled for March 4, 2014.

André Hoffmann, member since 1996; Dr. Andreas Oeri, member since 1996; Prof. Dr. Pius Baschera, member since 2007; Prof. Sir John Irving Bell, member since 2001; Paul Bulcke, member since 2011; Dr. Christoph Franz, member since 2011; Dame DeAnne Julius, member since 2002; Dr. Arthur D. Levinson, member since  2010; Dr. Severin Schwan, member since 2013; Peter R. Voser, member since 2011; Prof. Dr. Beatrice Weder di Mauro, member since 2006.

As announced on Sept. 16, 2013, the board proposes Christoph Franz to be elected as chairman of the board.

William M. Burns, member of the board of directors since 2010, has announced that he will not stand for re-election to the board of directors.

Source: Roche

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here